Valued at USD 5.81 billion in 2024, the base year, the viscosupplementation market is projected to reach USD 6.39 billion in 2025 and USD 15.26 billion by 2034, growing at a CAGR of 10.1% during the forecast period 2025–2034, per Polaris Market Research. Asia Pacific accounted for the largest share in 2024, while the orthopedic clinics/ASCs segment is expected to grow fastest from 2025 to 2034. Companies shaping the competitive landscape include Anika Therapeutics, Inc.; DePuy Synthes; F. Hoffmann-La Roche Ltd.; Ferring Pharmaceuticals B.V.; Fidia Farmaceutici S.p.A; LG Life Sciences Ltd.; Lifecore Biomedical; Sanofi; Seikagaku Corp.; Smith & Nephew PLC; and Zimmer Biomet.

Product Segmentation in the Viscosupplementation Market

By product, the market is divided into three injection, five injection, and single injection formats. The three injection segment held the largest share in 2024, as it is the preferred method among medical practitioners for treating osteoarthritis and is often favored because it reduces the need for total knee replacement surgery. The availability of various three injection options and approved clinical trials showing positive results also support the segment's dominance.

Meanwhile, the growing preference for single injection therapy is expected to drive market growth during the forecast period.

End Use: Outpatient Settings Accelerate

By end use, the market covers orthopedic clinics/ASCs and hospitals. The orthopedic clinics/ASCs segment is projected to grow fastest from 2025 to 2034, due to increased demand for outpatient surgeries. Orthopedic clinics specialize in musculoskeletal care, while ambulatory surgical centers conduct same-day surgeries for procedures such as ACL, hip, and knee surgery, enabling clinics to accommodate a higher volume of patients daily. These procedures are relatively uncomplicated and often require minimal hospitalization.

According to the Global RA Network, global arthritis prevalence surpassed 350 million people in 2021 and continues to rise, primarily because of the aging population. Hospitals are expected to see sustained growth, fueled by advances in medical technology and the development of multispecialty hospitals.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/viscosupplement-market  

Regional Dynamics

Asia Pacific led in 2024, supported by a growing elderly population, a rising prevalence of osteoarthritis, and increasing awareness of non-surgical treatment options. China, Japan, and India have seen significant demand because of large elderly populations and higher osteoarthritis incidence. Europe is projected to grow fastest during the forecast period, fueled by a growing geriatric population and increased investments from industry participants. According to the International Osteoporosis Foundation, 60.9% of women over 50 in the UK reported fractures from minor falls in October 2023, underscoring demand for effective joint care solutions.

Challenges and Strategic Responses

High treatment costs, limited insurance coverage, and variability in clinical outcomes continue to challenge adoption and accessibility. Pricing pressure, stringent regulations, and competition from corticosteroid injections and platelet-rich plasma therapy compel companies to keep innovating. Favorable reimbursement policies in Europe and increasing regulatory approvals in emerging markets intensify competition, while smaller players gain traction with cost-effective solutions in price-sensitive markets such as Asia Pacific and Latin America.

Recent Developments

• July 2024: LG Chem announced that its partner, Yifan Pharmaceutical, launched Synovian in China, a single-dose intra-articular osteoarthritis treatment marketed as Hyruan One.
• November 2022: Anika Therapeutics met the primary endpoint in its Phase III study for Cingal, formulated to offer prolonged pain relief in knee osteoarthritis, and is focused on securing FDA clearance.
• April 2022: Juniper Biologics and Kolon Life Sciences entered a licensing arrangement to develop and commercialize TissueGene-C low dose (TG-C LD), an investigational non-surgical therapy delivered through a single intra-articular injection.

Johnson & Johnson Services, Inc. (DePuy Synthes), based in New Brunswick, New Jersey, and Sanofi are among the large healthcare companies in the field. The report rates rivalry among existing firms as high.

Conclusion

The viscosupplementation market is expected to grow steadily due to the rising prevalence of osteoarthritis, an aging population, and increasing demand for minimally invasive joint pain treatments. Advancements in hyaluronic acid therapies and growing healthcare awareness are expected to create new opportunities, despite challenges related to treatment costs and varying clinical outcomes.

More Trending Latest Reports By Polaris Market Research:

top-10-largest-microfluidics-companies-in-2025

industrial-gases-market

dietary-supplements-market

kombucha-market

smart-cities-market

molecular-diagnostics-market

microgrid-market

application-modernization-services-market

cardiovascular-device-market